Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5587548 | 0.82 | ALDH1A1 (0.37) | HPGDTSHRHSD17B10MEN1ALDH1A1 | |
| SCHEMBL22279743 | 0.78 | CYP1A2 (0.31) | CYP1A2CYP3A4CYP2C9HIF1A | |
| SCHEMBL112121 | 0.74 | TSHR (0.50) | HPGDTSHRHSD17B10MEN1ALDH1A1 | |
| SCHEMBL4805327 | 0.72 | TSHR (0.47) | HPGDTSHRHSD17B10MEN1ALDH1A1 | |
| SCHEMBL12794176 | 0.72 | CYP1A2 (0.31) | CYP1A2CYP3A4CYP2C9HIF1A | |
| SCHEMBL28427396 | 0.69 | CYP1A2 (0.30) | CYP1A2CYP3A4CYP2C9HIF1A | |
| SCHEMBL23542368 | 0.69 | HSD17B10 (0.39) | HPGDTSHRHSD17B10ALDH1A1LMNA | |
| SCHEMBL122888 | 0.68 | CA2 (0.38) | TSHRALDH1A1LMNAMAPTCYP1A2 | |
| Pentachlorophenol SCHEMBL28030118 | 0.68 | HSD17B10 (0.83) | HPGDTSHRHSD17B10MEN1ALDH1A1 | |
| SCHEMBL68786 | 0.67 | HSD17B10 (0.82) | HPGDTSHRHSD17B10MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040987-B2 | Penam derivatives for treating bacterial infections | TENNOR THERAPEUTICS LIMITED (CN) | 2021-06-22 | — | — | US | disclosed |
| US-20210070774-A1 | PENAM DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | TENNOR THERAPEUTICS LIMITED (CN) | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070774-A1 | PENAM DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | BPGM, BLVRB, PREP | HPGD 916/4885TSHR 3703/4885HSD17B10 3493/4885 |
| US-11040987-B2 | Penam derivatives for treating bacterial infections | BPGM, BLVRB, PREP | HPGD 916/4885TSHR 3703/4885HSD17B10 3493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.